Defining the unmet needs in non-small cell lung cancer
Jean-Charles Soria, MD, PhD

Interactive clinical case―Personalizing first-line treatment in the absence of mutations
Martin Reck, MD, PhD

Interactive clinical case―Incorporating EGFR mutation status into first-line therapy selection
Luis Paz-Ares, MD, PhD

Interactive clinical case―Therapeutic decision making in the second-line
Mark A. Socinski, MD

After successful completion of this educational activity, participants should be able to:

• Define the clinical, histologic, and molecular factors that guide clinicians in selecting therapy for patients with NSCLC
• Outline appropriate treatment regimens for patients with NSCLC, focusing on how best to tailor therapeutic choices to patient characteristics such as tissue histology, presence or absence of molecular markers, and comorbidities
• Analyze available and emerging treatment options in advanced NSCLC, including maintenance therapy, second-line therapy, and beyond
• Identify areas of uncertainty or controversy requiring further clarification regarding the use of patient and disease characteristics as guides for treatment selection at various stages of disease progression in the management of NSCLC

In accordance with the ACCME Standards for Commercial Support, educational activities sponsored by prIME Oncology must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in a prIME Oncology–sponsored activity are required to disclose any relevant financialinterest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Dr Perez-Soler has disclosed that he has received consulting fees from Lilly and Genentech.

Dr Reck has disclosed that he has received consulting fees from F. Hoffmann-La Roche, Lilly, Pfizer, Bristol-Myers Squibb, and AstraZeneca. He has also disclosed he has participated in speakers’ bureaus for F. Hoffmann-La Roche, Lilly, and AstraZeneca.

Dr Paz-Ares has disclosed that he is a consultant for Novartis, Celgene, and Ortho Biotech.

Dr Socinski has disclosed that he has participated in speakers’ bureaus for Genentech. He has also performed contracted research for Genentech, Lilly, Pfizer, Synta, and Celgene.

Dr Soria has disclosed that he has received consulting fees from Abbott, Bristol-Myers Squibb, Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Lilly, Merck Serono, MSD, Pfizer, Roche, and sanofi-aventis.

The employees of prIME Oncology have disclosed:

• Bojana Pajk, MD, MSc (clinical) – no relevant financial relationships to disclose.
• Trudy Stoddert, ELS (editorial) – no relevant financial relationships to disclose.
• Susan H. Yarbrough, CCMEP (compliance) – no relevant financial relationships to disclose.

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

To participate in this activity, your computer should have a processor the equivalent of Intel Pentium II 450 MHz or faster, with 128MB of RAM and a connection to the Internet.

Estimated time to complete activity: 60 minutes